Phase 2
N=17
External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma
Soft Tissue Sarcoma
Bottom Line
View on ClinicalTrials.gov: NCT00365872 ↗Enrolled (actual)
17
Serious AEs
29.4%
Results posted
Jan 2014
Primary outcome: Primary: Overall Response Rate (ORR) — 9; 3; 6 participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Dendritic Cell (DC) Injections (Biological); Radiation therapy (Procedure); Complete Resection - Surgery for tumor removal (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Primary completion
- Jun 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Overall Response Rate (ORR) |
9; 3; 6 | — |
| SECONDARY Occurrence of Significant (>/= Grade 2) Toxicity |
— | — |
| SECONDARY Occurrence of Postoperative Wound Complications |
5 | — |
| SECONDARY Participants With No Evidence of Disease at Follow-up |
12; 6; 4 | — |
Summary
This is a Phase II study using a combination of external beam radiation with intratumoral injection of dendritic cells (white blood cells) as neo-adjuvant treatment for patients with high-risk soft tissue sarcoma. The purpose was to determine if an injection of the patient's own immune related white blood cells into their tumor would strengthen the immune system to fight against their cancer.
Eligibility Criteria
Inclusion Criteria
- Intermediate or high grade sarcoma as determined by pathology review
- Musculoskeletal tumor in extremities, trunk or chest wall.
- Primary tumor or isolated locally recurrent tumor greater than 5 cm in diameter.
- Clinical Stage T2N0M0 (AJCC 6th edition)
- Patient is not a candidate for neoadjuvant chemotherapy.
- Performance status Eastern Cooperative Oncology Group (ECOG) 0 or 1.
- No steroid therapy within 4 weeks of first dendritic cell administration.
- No coagulation disorder.
- Patient's written informed consent.
- No contraindication to resection.
- Adequate organ function (measured within a week of beginning treatment).
- White blood count (WBC) > 3, 000/mm to the third power and absolute neutrophil count (ANC) >1500/mm to the third power
- Platelets > 100, 000/mm to the third power
- Hematocrit > 25%
- Bilirubin 60 mL/min
- Radiation Oncologist must confirm that a 2-3 cm strip of skin can be spared from radiation.
Exclusion Criteria
- Retroperitoneal location.
- Gastrointestinal stromal tumor (GIST).
- Demonstrated metastatic disease.
- Prior radiation therapy if the current tumor is locally recurrent after prior resection.
- Concurrent treatment with any anticancer agent other than radiation as dictated by the protocol.
- Bleeding disorder.
- H.I.V. infection or other primary immunodeficiency disorder.
- Ongoing systemic therapy with immunosuppressant drugs (e.g. corticosteroids, azathioprine, cyclosporin, methotrexate).
- Any serious ongoing infection.
- Pregnant or lactating women -- Patients in reproductive age must agree to use contraceptive methods for the duration of the study (a pregnancy test will be obtained before treatment).
- ECOG performance status of 2, 3 or 4.
Data sourced from ClinicalTrials.gov (NCT00365872). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.